Top-10 Pharmaceutical Company Selects Cegedim Dendrite's Aggregate Spend Solution

Top-10 Pharmaceutical Company Selects Cegedim Dendrite's Aggregate Spend Solution


Proven Industry-Leading Solution Will Be Used To Comply With Complex
State & Federal Promotional Spend Reporting Regulations

 

Bedminster, NJ - May 28, 2009 - Cegedim Dendrite today announced that its Aggregate Spend and State Services solution, State GuardianTM, has been selected by a Top-10 Pharmaceutical Company. Cegedim Dendrite is the leading provider of innovative Compliance Solutions to the pharmaceutical industry, and has been offering its break-through State GuardianTM solution, in both SaaS and license models, since 2006.

State GuardianTM is a cost-effective and easy-to-implement solution that helps pharmaceutical companies of all sizes ensure compliance with the state and federal laws and regulations that govern gifts, marketing and advertising expenses, as well as other promotional items related to prescription drugs. It collects data from disparate systems and automatically generates reports per the latest state and federal requirements. State GuardianTM integrates with any Customer Relationship Management (CRM) solution.

The Top-10 Pharmaceutical Company will utilize Cegedim Dendrite's State GuardianTM solution to compile and prepare required state reports automatically, removing a tremendous administrative burden, and aiding in compliance with increasingly complex, multi-state requirements and potentially federal reporting requirements. The solution also provides the benefit of multiple views into aggregate spending at the prescriber, product and event levels, enabling improved tracking.

"This Top-10 Pharmaceutical Company is an industry leader and their selection of State Guardian reaffirms our market leadership which was established in 2006," explained Bill Buzzeo, Cegedim Dendrite VP & GM, Compliance and OneKey Solutions.

"We were the first to bring a commercially available solution of this kind to market and we continue to expand its breadth and adapt it to meet the needs of emerging, mid-sized and large pharmaceutical companies," said Buzzeo. "This customer chose State GuardianTM because of Cegedim Dendrite's experience and expertise, especially compared to competitors who are only just entering the market. As one decision factor, the customer did not want to invest in an unproven solution. Customers look for proven solutions and experience to help them meet their needs today and tomorrow. We have been supporting the Life Sciences industry for the past 40 years."

About Cegedim Dendrite

Cegedim Dendrite is the life sciences industry's leading provider of Customer Relationship Management (CRM) solutions. Pharmaceutical by design, the company's innovative business solutions and global reach incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Dendrite enables more than 200,000 users in many of the world's top companies stay ahead of market challenges. Cegedim Dendrite also provides sales, marketing and regulatory compliance solutions in more than 80 countries.

Cegedim Dendrite is part of the France-based Cegedim S.A. Group.

To learn more, please visit: www.cegedimdendrite.com.

About CEGEDIM:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies. The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,400 people in 80 countries and generated revenue of €849 million in 2008. To learn more, please visit our website: www.cegedim.com.

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.